Detection of gene promoter hypermethylation in the tumor and serum of patients with gastric carcinoma.

PURPOSE Aberrant promoter methylation, an alternative mechanism for gene silencing, is frequently detected in gastric cancer. We studied the feasibility of detecting aberrant methylation in serum of gastric cancer patients. EXPERIMENTAL DESIGN Patients (54) with gastric adenocarcinoma were studied. The tumor and the paired serum were examined for aberrant methylation in DAP-kinase, E-cadherin, GSTP1, p15, and p16 by methylation-specific PCR. Serum from 30 age-matched noncancer patients was used as control. RESULTS Promoter methylation in DAP-kinase, E-cadherin, GSTP1, p15, and p16 were detected in 70.3, 75.9, 18.5, 68.5, and 66.7% of primary tumor. In serum of gastric cancer patients, methylation in DAP-kinase, E-cadherin, GSTP1, p15, and p16 were detected in 48.1, 57.4, 14.8, 55.6, and 51.9%, respectively. None of the control serum showed aberrant methylation. Aberrant methylation in serum DNA was all accompanied with methylation in the corresponding tumor samples. In general, >60% of serum from cancers with aberrant methylation demonstrated these epigenetic alterations. CONCLUSION Our findings suggest that aberrant promoter methylation in serum can be detected in a substantial proportion of gastric cancer patients, and this strategy should be evaluated in the screening and surveillance of gastric cancer.

[1]  A. Nakao,et al.  Molecular detection of p16 promoter methylation in the serum of patients with esophageal squamous cell carcinoma. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[2]  Jun Yu,et al.  Concurrent hypermethylation of multiple tumor‐related genes in gastric carcinoma and adjacent normal tissues , 2001, Cancer.

[3]  J. Guarner,et al.  Screening markers for chronic atrophic gastritis in Chiapas, Mexico. , 2001, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[4]  G. Kang,et al.  Correlation of p16 Hypermethylation with p16 Protein Loss in Sporadic Gastric Carcinomas , 2000, Laboratory Investigation.

[5]  W. Leung,et al.  Concurrent hypermethylation of multiple tumor related genes in gastric cancer , 2000 .

[6]  J. Herman,et al.  Gene promoter hypermethylation in tumors and serum of head and neck cancer patients. , 2000, Cancer research.

[7]  J. Ferlay,et al.  Erratum: Estimates of the worldwide mortality from 25 cancers in 1990. Int. J. Cancer, 83, 18–29 (1999). , 1999, International journal of cancer.

[8]  S. Baylin,et al.  Aberrant methylation in gastric cancer associated with the CpG island methylator phenotype. , 1999, Cancer research.

[9]  J. Ferlay,et al.  Estimates of the worldwide mortality from 25 cancers in 1990 , 1999, International journal of cancer.

[10]  Jose M. Silva,et al.  Presence of tumor DNA in plasma of breast cancer patients: clinicopathological correlations. , 1999, Cancer research.

[11]  M A Fujino,et al.  Accuracy of screening for gastric cancer using serum pepsinogen concentrations , 1999, Gut.

[12]  R. Lambert.  Mass Screening Programs in Japan: What Can We Learn in the West? , 1998, Endoscopy.

[13]  J. Jen,et al.  Molecular detection of genetic alterations in the serum of colorectal cancer patients. , 1998, Cancer research.

[14]  M. Farthing,et al.  A prospective study of K-ras mutations in the plasma of pancreatic cancer patients. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[15]  Y. Bang,et al.  Alterations of p16INK4A and p15INK4B genes in gastric carcinomas , 1997, Cancer.

[16]  J. Herman,et al.  Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[17]  B. Shapiro,et al.  Free DNA in the serum of cancer patients and the effect of therapy. , 1977, Cancer research.

[18]  P. Laurén,et al.  THE TWO HISTOLOGICAL MAIN TYPES OF GASTRIC CARCINOMA: DIFFUSE AND SO-CALLED INTESTINAL-TYPE CARCINOMA. AN ATTEMPT AT A HISTO-CLINICAL CLASSIFICATION. , 1965, Acta pathologica et microbiologica Scandinavica.

[19]  鈴木 拓.  Distinct methylation pattern and microsatellite instability in sporadic gastric cancer , 2000 .

[20]  W. Lau,et al.  Detection of aberrant p16 methylation in the plasma and serum of liver cancer patients. , 1999, Cancer research.

[21]  J. Herman,et al.  Detection of aberrant promoter hypermethylation of tumor suppressor genes in serum DNA from non-small cell lung cancer patients. , 1999, Cancer research.

[22]  S. Leung,et al.  hMLH1 promoter methylation and lack of hMLH1 expression in sporadic gastric carcinomas with high-frequency microsatellite instability. , 1999, Cancer research.